Morishita Jintan Co., Ltd. (4524.T)
JPY 2065.0
(-0.24%)
JPY 2065.0
(-0.24%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 5.28 Billion JPY | 11.4% |
| 2022 | 4.73 Billion JPY | 3.61% |
| 2021 | 4.57 Billion JPY | 0.33% |
| 2020 | 4.55 Billion JPY | 1.97% |
| 2019 | 4.46 Billion JPY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 1.21 Billion JPY | -22.56% |
| 2023 Q3 | 1.22 Billion JPY | -7.96% |
| 2023 Q2 | 1.33 Billion JPY | 15.83% |
| 2023 Q4 | 1.56 Billion JPY | 27.98% |
| 2023 FY | 5.27 Billion JPY | 11.4% |
| 2023 Q1 | 1.15 Billion JPY | -13.6% |
| 2022 Q3 | 1 Million JPY | -99.92% |
| 2022 FY | 4.73 Billion JPY | 3.61% |
| 2022 Q4 | 1.33 Billion JPY | 133000.0% |
| 2022 Q2 | 1.17 Billion JPY | 0.0% |
| 2021 FY | 4.57 Billion JPY | 0.33% |
| 2020 FY | 4.55 Billion JPY | 1.97% |
| 2019 FY | 4.46 Billion JPY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 43.63 Billion JPY | 87.896% |
| Takeda Pharmaceutical Company Limited | 2618.18 Billion JPY | 99.798% |
| Sumitomo Pharma Co., Ltd. | 542.17 Billion JPY | 99.026% |
| Shionogi & Co., Ltd. | 197.62 Billion JPY | 97.327% |
| Wakamoto Pharmaceutical Co.,Ltd. | 3.73 Billion JPY | -41.368% |
| Nippon Shinyaku Co., Ltd. | 65.63 Billion JPY | 91.952% |
| Kaken Pharmaceutical Co., Ltd. | 29.02 Billion JPY | 81.803% |
| Eisai Co., Ltd. | 533.01 Billion JPY | 99.009% |
| Hisamitsu Pharmaceutical Co., Inc. | 65.8 Billion JPY | 91.973% |
| Mochida Pharmaceutical Co., Ltd. | 46.26 Billion JPY | 88.584% |
| Fuso Pharmaceutical Industries,Ltd. | 11.55 Billion JPY | 54.28% |
| Nippon Chemiphar Co., Ltd. | 8.23 Billion JPY | 35.836% |
| Tsumura & Co. | 48.8 Billion JPY | 89.176% |
| Kissei Pharmaceutical Co., Ltd. | 33.32 Billion JPY | 84.15% |
| Torii Pharmaceutical Co., Ltd. | 19.53 Billion JPY | 72.964% |
| Towa Pharmaceutical Co., Ltd. | 63.73 Billion JPY | 91.713% |
| Fuji Pharma Co., Ltd. | 12.65 Billion JPY | 58.268% |
| Zeria Pharmaceutical Co., Ltd. | 40.46 Billion JPY | 86.947% |
| KYORIN Holdings, Inc. | 45.39 Billion JPY | 88.364% |
| Taiko Pharmaceutical Co.,Ltd. | 4.15 Billion JPY | -27.063% |
| Daito Pharmaceutical Co.,Ltd. | 5.94 Billion JPY | 11.152% |
| SymBio Pharmaceuticals Limited | 5.22 Billion JPY | -1.136% |
| MedRx Co., Ltd | 959 Million JPY | -450.782% |
| Mizuho Medy Co.,Ltd. | 2.87 Billion JPY | -83.803% |
| Solasia Pharma K.K. | 1.47 Billion JPY | -257.859% |
| Modalis Therapeutics Corporation | 2.37 Billion JPY | -122.807% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 24.16 Billion JPY | 78.142% |
| Sawai Group Holdings Co., Ltd. | 35.43 Billion JPY | 85.093% |
| Cyfuse Biomedical K.K. | 735.18 Million JPY | -618.463% |
| Toho Holdings Co., Ltd. | 99.81 Billion JPY | 94.708% |
| Koa Shoji Holdings Co.,Ltd. | 2.25 Billion JPY | -133.998% |